Physician profile
Robert A Davis
NPI 1801821491
$9,108.14
in general payments reported to CMS, 2019-2025
33 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $1,082 · 2021: $1,869 · 2022: $1,723 · 2023: $1,109 · 2024: $1,120 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,451.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,709.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $954.78 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $932.95 | 2021-2025 | Vraylar, Ubrelvy, Viberzi |
| Astrazeneca Pharmaceuticals LP | $881.09 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $644.66 | 2019-2025 | |
| Glaxosmithkline, LLC. | $602.42 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $475.78 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $460.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $374.64 | 2019-2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $189.37 | 2019-2022 | |
| Sanofi Pasteur INC. | $187.08 | 2020 | |
| Supernus Pharmaceuticals, INC. | $186.86 | 2023-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $182.79 | 2019-2023 | Belsomra, Steglatro |
| Amgen INC. | $174.72 | 2020-2022 | |
| Exact Sciences Corporation | $149.36 | 2023-2025 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $140.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.02 | 2022-2025 | |
| Abbott Laboratories | $98.50 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Eisai INC. | $94.00 | 2020-2022 | |
| Esperion Therapeutics, INC. | $66.31 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $62.54 | 2021 | |
| Currax Pharmaceuticals LLC | $62.35 | 2022-2024 | Contrave |
| Allergan, INC. | $57.74 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.38 | 2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $47.71 | 2020-2021 | |
| Medtronic, INC. | $43.03 | 2022 | |
| Amarin Pharma, INC. | $30.32 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $27.34 | 2019 | |
| Inspire Medical Systems, INC. | $22.83 | 2025 | Inspire |
| Hologic Sales and Service, LLC | $16.64 | 2021 | |
| Phadia US INC. | $15.94 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.28 | 2023 | Quviviq |
| Genentech USA, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.